• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Adding four doses of rituximab did not significantly improve event-free survival over standard of care in acute lymphoblastic leukaemia

byKathleen Lau
April 8, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

RELATED REPORTS

SEP-1 sepsis management bundle not associated with improved mortality

#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

Tags: acute lymphoblastic leukemiaB-cell acute lymphoblastic leukemiaevent-free survivalmortality outcomesrituximab
Previous Post

Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis – the ASCEND-ID trial

Next Post

2 Minute Medicine Rewind April 11, 2022

RelatedReports

Hypotonic IVF linked to increased risk of hyponatremia
Infectious Disease

SEP-1 sepsis management bundle not associated with improved mortality

February 17, 2025
#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children
StudyGraphics

#VisualAbstract: Blinatumomab Improves Survival in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children

December 20, 2024
#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk
StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024
#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer
StudyGraphics

#VisualAbstract: Perioperative Durvalumab with Neoadju-vant Chemotherapy Improved Survival in Operable Bladder Cancer

September 27, 2024
Next Post
Compliance-linked incentives increase infant immunizations rates in rural India

2 Minute Medicine Rewind April 11, 2022

Preterm birth associated with lower high school academic performance

Mindfulness and compassion-based program may improve wellbeing in university students

Few older adolescents meet recommended levels of physical activity

Exercise during early-stage breast cancer decreases health care utilization

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • Large language models show potential to provide feedback on research papers on a large-scale
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.